MDxHealth SA
Business
MDxHealth SA is a commercial-stage precision diagnostics company providing non-invasive molecular tests for prostate cancer detection, diagnosis, and treatment monitoring, as well as urinary tract infection management. The company's core test menu includes Exo mdx (urine-based risk assessment), Confirm mdx (tissue-based biopsy validation), GPS mdx (tissue-based prognostic scoring), and Resolve mdx (PCR-based UTI pathogen identification with personalized antibiotic recommendations). MDxHealth operates CAP-accredited, CLIA-certified laboratory facilities in California, Texas, and Massachusetts, markets directly to U.S. urologists through a field sales force, and has achieved Medicare reimbursement and NCCN guideline recognition for its primary tests.
Summary from 20-F filed 2026-04-03
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-33.50M |
| Total assets | $147.95M |
| Total liabilities | $160.05M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is MDxHealth SA's CIK number?
MDxHealth SA's SEC CIK number is 0001872529 (1872529). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MDxHealth SA's SEC filings?
All of MDxHealth SA's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.